HLA-G and breast carcinoma: High levels of HLA‐G+ TDEs in peripheral blood samples of breast cancer patients receiving neoadjuvant chemotherapy were also associated with disease progression, whereas high levels of soluble HLA‐G were associated with improved clinical outcomes.